Proteomic and glycosylation biomarkers show promise for early rheumatoid arthritis diagnosis and personalized therapy

Rheumatoid arthritis (RA) is a chronic autoimmune disease causing progressive joint inflammation and damage. Early diagnosis is critical for effective intervention, yet challenging due to an initial asymptomatic inflammatory phase. Current biomarkers like anti-citrullinated-protein antibodies (ACPA) and rheumatoid factor (RF) lack specificity, prompting a search for more robust alternatives. Advanced proteomic and glycosylation analyses offer a comprehensive approach to scrutinize a range of biomolecules, addressing this diagnostic gap and paving the way for precision medicine in RA.

This review systematically analyzed existing literature on proteomic and glycosylation approaches for rheumatoid arthritis (RA) biomarker discovery. Researchers synthesized findings from studies that employed advanced analytical techniques such as MALDI-MS, Q-TOF, and SELDI-TOF. The scope included examining various biomolecules—from citrullinated-proteins and peptides to novel protein candidates—in biological fluids (e.g., synovial fluid, plasma, serum) and tissues. The review also explored the application of proteomics in monitoring disease progression and treatment response to anti-rheumatic drugs.

The review identified several promising proteinaceous species as potential rheumatoid arthritis (RA) biomarkers. Key candidates include citrullinated-proteins, thymosin, macrophage-capping protein, calgranulins, and serum amyloid-A, which show potential for early diagnosis. Proteomics-based approaches were highlighted for their ability to monitor specific changes within the RA proteome, revealing glycosylated VCAM1/SEMA4D proteins and GFAP/A1BG auto-antibodies as novel diagnostic and prognostic markers.

The systematic analysis underscored the utility of advanced techniques like MALDI-MS, Q-TOF, and SELDI-TOF in uncovering these complex biomolecular signatures. Furthermore, the review discussed treatment-responsive markers, such as the S100A8/A9 heterocomplex and leucine-rich alpha-2 glycoprotein, demonstrating their potential for monitoring drug efficacy and guiding personalized therapeutic interventions in RA management.